NCT01904318

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer

A Dose Block-randomized, Doubled, Placebo-controlled, Single Dose, Dose-escalation Clinical Phase I Study to Evaluate the Safety, Pharmacokinetics and Food

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: IlDong Pharmaceutical Co Ltd · Industry
• Sex: Male
• Age: 20 Years – 50 Years
• Healthy volunteers: Accepted

Summary

A dose block-randomized, double-blinded, placebo-controlled, single dose, dose-escalation clinical phase I study to evaluate the safety, pharmacokinetics and food effect of IDP-73152 mesylate after oral administration in healthy male volunteer

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	IDP-73152 mesylate 40 mg	IDP-73152 mesylate 40 mg single dose administration
DRUG	IDP-73152 mesylate 80 mg	IDP-73152 mesylate 80 mg single dose administration
DRUG	IDP-73152 mesylate 160 mg	IDP-73152 mesylate 160 mg single dose administration
DRUG	IDP-73152 mesylate 320 mg	IDP-73152 mesylate 320 mg single dose administration
DRUG	IDP-73152 mesylate 640 mg	IDP-73152 mesylate 640 mg single dose administration
DRUG	IDP-73152 mesylate 1280 mg	IDP-73152 mesylate 1280 mg single dose administration
DRUG	Placebo	Placebo single dose administration

Timeline

• Start date: 2013-07-01
• Primary completion: 2013-12-01
• Completion: 2014-01-01
• First posted: 2013-07-22
• Last updated: 2014-02-12

Locations

1 site across 1 country: South Korea